SEC Tracker
Get the app

Drugs Made In America Acquisition DMAA

Drugs Made In America Acquisition amends merger agreement

Merger communication

Form
425
Filed
Importance
Routine
  1. Amendment No. 1 to merger agreement dated September 8, 2026
  2. Closing Valuation of $2.85B if APQC Acquisition completes by November 1, 2026
  3. Standalone Closing Valuation of $1.71B if APQC Acquisition not completed by November 1, 2026

Written from the 425 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Drugs Made In America Acquisition files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 6770 and related industry codes: the same peer list as the financial tables.

  1. Archimedes Tech SPAC Partners II ATII public float $235M, Jun 30, 2025
  2. Fifth Era Acquisition Corp I FERA public float $236M, Jun 30, 2025
  3. Sizzle Acquisition Corp. II SZZL public float $233M, Jun 30, 2025
  4. GSR IV Acquisition GSRF public float $236M, Jun 30, 2025
  5. Jena Acquisition Corp II JENA public float $236M, Jun 30, 2025